Darren Snellgrove
Senior VP & CFOMr. Darren Snellgrove is Chief Financial Officer of Halozyme Therapeutics, Inc. from June 8, 2026 and serves as Senior Vice President. He was Vice President of Investor Relations of Johnson & Johnson. Mr. Snellgrove served as Chief Financial Officer of Johnson & Johnson's Pharmaceuticals sector, where he provided global financial leadership. He was Vice President, Finance for Janssen Research & Development. He was Vice President, Finance and Operations for Johnson & Johnson Innovation. He joined Johnson & Johnson through the acquisition of Centocor in 1999, where he spent a number of years in roles of increasing responsibility supporting a variety of functions, including Commercial, R&D and Business Development. Beginning in 2002, he spent three years in J&J’s Mergers and Acquisitions Finance group, providing financial leadership on over 100 potential acquisitions, major licensing deals, equity investments, options, structures and divestitures across all sectors. Prior to joining the Johnson & Johnson Innovation Organization, he was VP of Finance and Procurement, Chief Financial Officer at Janssen AI. He holds a BA Honors degree in Economics and Philosophy from Southampton University in England and an MBA from Villanova University.
Positions
- Company NameHalozyme Therapeutics, Inc.Stock CodeHALOPositionSenior VP & CFOColleagues
- HIHelen I. TorleyPresident, CEO & Director
- JWJeffrey W. HendersonIndependent Chair of the Board
- MSMark SnyderExecutive VP, General Counsel, Chief Compliance Officer & Corporate Secretary
- BSBrian SweeneyChief Human Resources Officer
- DADavid A. RamsayPresident of Drug Delivery
- GIGregory I. FrostChairman of Scientific Advisory Board
- MLMatthew L. PosardIndependent Director
- BMBernadette Mary ConnaughtonIndependent Director
